RELEASE: SIBIONICS achieves a milestone: The CE marking of its innovative GS1 continuous glucose monitoring system

SHENZHEN, China, Nov.

RELEASE: SIBIONICS achieves a milestone: The CE marking of its innovative GS1 continuous glucose monitoring system

SHENZHEN, China, Nov. 1, 2023/PRNewswire/ -- SIBIONICS, the world's third largest brand of continuous glucose monitoring (CGM) systems, is pleased to announce that it has received CE marking for its revolutionary GS1 CGM. This important milestone marks a momentous achievement for SIBIONICS, facilitating the distribution and utilization of this revolutionary technology throughout the European market.

The CE marking, also known as "Conformité Européene" or "European Conformity", is a certification that confirms that a product meets the health and safety standards of the European Union (EU) and serves as proof of its quality, safety and effectiveness. .

Founded in 2015, SIBIONICS has a workforce of more than 700 people, of which more than 40% are actively involved in research and development activities. To date, SIBIONICS has collaborated with 1,600 hospitals to integrate GS1 CGM for inpatient treatment, benefiting more than 600,000 users worldwide in managing their diabetes. With an annual production capacity of 6,000,000 units and consistently achieving a low MARD value of 8.83% in each batch, SIBIONICS is well equipped to serve a broader customer base.

At its core, the SIBIONICS GS1 CGM system is designed to provide both healthcare professionals and patients with the information needed to make informed treatment decisions and maintain optimal glucose control.

The SIBIONICS GS1 CGM offers users 14 days of calibration-free continuous glucose monitoring solution, giving them the ability to transmit glucose data to their monitoring devices or mobile applications and generate professional AGP reports. To help users better manage diabetes, the GS1 CGM also makes it easy to share data with friends and family while seamlessly integrating the latest ProView remote access platform. In this way, health professionals can monitor remotely and carry out the timely medical interventions that are necessary.

As an innovative medical technology company that combines medical technology with artificial intelligence, SIBIONICS is committed to extending its innovative and revolutionary technology and expertise in diabetes management to more diabetic patients around the world.

At the same time, SIBIONICS is vigorously expanding its presence in various specialized segments within the area of ​​healthcare management. Its successful launch of the KS1 continuous ketone monitoring (CKM) system, a consumer bioreceptor, has received enthusiastic applause from consumers.

Starting today, SIBIONICS GS1 CGM products will gradually be available for pre-sale in EU countries, the United Kingdom and other European countries. Those interested can find more information on the official website at


Photo - -

View original content to download multimedia: